Safety evaluation for lingnan characteristic ointment based on intelligent navigation

注册号:

Registration number:

ITMCTR1900002528

最近更新日期:

Date of Last Refreshed on:

2019-08-16

注册时间:

Date of Registration:

2019-08-16

注册号状态:

Registration Status:

预注册

Prospective registration

注册题目:

基于智能导航的岭南特色膏方安全性评价

Public title:

Safety evaluation for lingnan characteristic ointment based on intelligent navigation

注册题目简写:

English Acronym:

研究课题的正式科学名称:

基于智能导航的岭南特色膏方安全性评价

Scientific title:

Safety evaluation for lingnan characteristic ointment based on intelligent navigation

研究课题的正式科学名称简写:

Scientific title acronym:

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

ChiCTR1900025208 ; ChiMCTR1900002528

申请注册联系人:

王永福

研究负责人:

唐洪梅

Applicant:

Yongfu Wang

Study leader:

Hongmei Tang

申请注册联系人电话:

Applicant telephone:

+86 15013093537

研究负责人电话:

Study leader's telephone:

+86 020-86358342, +86 13924022239

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

675461163@qq.com

研究负责人电子邮件:

Study leader's E-mail:

tanghongmei2000@163.com

申请单位网址(自愿提供):

Study leader's website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website
(voluntary supply):

申请注册联系人通讯地址:

广州市白云区机场路16号

研究负责人通讯地址:

广州市白云区机场路16号

Applicant address:

16 Airport Road, Baiyun District, Guangzhou, Guangdong, China

Study leader's address:

16 Airport Road, Baiyun District, Guangzhou, Guangdong, China

申请注册联系人邮政编码:

Applicant postcode:

510405

研究负责人邮政编码:

Study leader's postcode:

510405

申请人所在单位:

广州中医药大学第一临床医学院

Applicant's institution:

The First School of Clinical Medicine, Guangzhou University of Chinese Medicine

是否获伦理委员会批准:

Approved by ethic committee:

伦理委员会批件文号:

Approved No. of ethic committee:

ZYYECK【2019】050

伦理委员会批件附件:

Approved file of Ethical Committee:

View

批准本研究的伦理委员会名称:

广州中医药大学第一附属医院伦理委员会

Name of the ethic committee:

Ethics Committee of the First Affiliated Hospital of Guangzhou University of Traditional Chinese Medicine

伦理委员会批准日期:

Date of approved by ethic committee:

2019/7/1 0:00:00

伦理委员会联系人:

黎欣盈

Contact Name of the ethic committee:

Li Xinying

伦理委员会联系地址:

广州市白云区机场路16号

Contact Address of the ethic committee:

16 Airport Road, Baiyun District, Guangzhou, Guangdong, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 020-36588667, 36591965

伦理委员会联系人邮箱:

Contact email of the ethic committee:

gztcmlunli@163.com

研究实施负责(组长)单位:

广州中医药大学第一附属医院药学部

Primary sponsor:

Pharmaceutical Department, the First Affiliated Hospital of Guangzhou University of Chinese Medicine

研究实施负责(组长)单位地址:

广州市白云区机场路16号

Primary sponsor's address:

16 Airport Road, Baiyun District, Guangzhou, Guangdong, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

广东

市(区县):

广州

Country:

China

Province:

Guangdong

City:

Guangzhou

单位(医院):

广州中医药大学第一附属医院

具体地址:

白云区机场路16号

Institution
hospital:

The First Affiliated Hospital of Guangzhou University of Chinese Medicine

Address:

16 Airport Road, Baiyun District

经费或物资来源:

广州中医药大学第一附属医院

Source(s) of funding:

The First Affiliated Hospital of Guangzhou University of Chinese Medicine

研究疾病:

基于智能导航的岭南特色膏方安全性评价

研究疾病代码:

Target disease:

Safety evaluation of lingnan characteristic ointment based on intelligent navigation

Target disease code:

研究类型:

Study type:

观察性研究

Observational study

研究设计:

Study design:

连续入组

Sequential

研究所处阶段:

Study phase:

探索性研究/预试验

Pilot clinical trial

研究目的:

1. 获得我院岭南特色膏方不良反应发生率及其影响因素。 2. 评价岭南特色膏方的安全性,及时有效控制膏方用药风险。

Objectives of Study:

1. Obtain the incidence of adverse reactions and its influencing factors in Lingnan specialty ointment in our hospital. 2. Evaluate the safety of the Lingnan specialty ointment and effectively control the risk of the ointment.

药物成份或治疗方案详述:

岭南特色膏方 不干预治疗

Description for medicine or protocol of treatment in detail:

Lingnan specialty ointment Non-intervention therapy

纳入标准:

2019年9月1号-2020年6月1号间在我院门诊就诊或住院所有服用膏方的患者。

Inclusion criteria

Patients who took ointment in our outpatient department and inpatient department from September 1, 2019 to June 1, 2020.

排除标准:

Exclusion criteria:

None

研究实施时间:

Study execute time:

From 2019-07-01

To      2020-12-31

征募观察对象时间:

Recruiting time:

From 2019-09-01

To      2020-06-01

干预措施:

Interventions:

组别:

Case series

样本量:

5000

Group:

Case series

Sample size:

干预措施:

岭南特色膏方

干预措施代码:

Intervention:

lingnan characteristic ointment

Intervention code:

样本总量 Total sample size : 5000

研究实施地点:

Countries of recruitment
and research settings:

国家:

中国

省(直辖市):

广东

市(区县):

广州

Country:

China

Province:

Guangdong

City:

Guangzhou

单位(医院):

广州中医药大学第一附属医院

单位级别:

三级甲等

Institution/hospital:

The First Affiliated Hospital of Guangzhou University of Chinese Medicine

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

心电图

指标类型:

主要指标

Outcome:

Electrocardiogram

Type:

Primary indicator

测量时间点:

患者来院就医时

测量方法:

医院管理信息系统查询

Measure time point of outcome:

When the patient comes to the hospital

Measure method:

From the hospital information system (HIS) query

指标中文名:

肾功能

指标类型:

主要指标

Outcome:

Renal function

Type:

Primary indicator

测量时间点:

患者来院就医时

测量方法:

医院管理信息系统查询

Measure time point of outcome:

When the patient comes to the hospital

Measure method:

From the hospital information system (HIS) query

指标中文名:

血常规

指标类型:

主要指标

Outcome:

Blood routine

Type:

Primary indicator

测量时间点:

患者来院就医时

测量方法:

医院管理信息系统查询

Measure time point of outcome:

When the patient comes to the hospital

Measure method:

From the hospital information system (HIS) query

指标中文名:

大便常规

指标类型:

主要指标

Outcome:

Stool routine

Type:

Primary indicator

测量时间点:

患者来院就医时

测量方法:

医院管理信息系统查询

Measure time point of outcome:

When the patient comes to the hospital

Measure method:

From the hospital information system (HIS) query

指标中文名:

尿常规

指标类型:

主要指标

Outcome:

Urine routine

Type:

Primary indicator

测量时间点:

患者来院就医时

测量方法:

医院管理信息系统查询

Measure time point of outcome:

When the patient comes to the hospital

Measure method:

From the hospital information system (HIS) query

指标中文名:

肝功能

指标类型:

主要指标

Outcome:

Liver function

Type:

Primary indicator

测量时间点:

患者来院就医时

测量方法:

医院管理信息系统查询

Measure time point of outcome:

When the patient comes to the hospital

Measure method:

From the hospital information system (HIS) query

采集人体标本:

Collecting sample(s)
from participants:

征募研究对象情况:

尚未开始

Not yet recruiting

年龄范围:

最小
Min age years
最大
Max age years

Recruiting status:

Participant age:

性别:

Gender:

男女均可

Both

随机方法(请说明由何人用什么方法产生随机序列):

未使用

Randomization Procedure (please state who generates the random number sequence and by what method):

Not used

盲法:

N/A

Blinding:

N/A

是否共享原始数据:

IPD sharing:

Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

ResMan, http://www.medresman.org

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

ResMan, http://www.medresman.org

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

使用ResMan管理临床试验(www.medresman.org)

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Clinical trials were administered using ResMan(www.medresman.org)

数据管理委员会:

Data Managemen Committee:

Yes

研究计划书或研究结果报告发表信息
(杂志名称、期、卷、页,时间;或网址):

Publication information of the protocol/research results report
(name of the journal, volume, issue, pages, time; or website):

ITMCTR BJ-ICP:07032215-5 Tip: IE8 is recommended Use the system with widescreen display resolution above